AstraZeneca in merger talks with Bristol Myers Squibb, FT reports

AstraZeneca ↘ 0.99% has been exploring a deal to combine with Bristol Myers Squibb Bristol-Myers Squibb Company ↗ 0.69%, the Financial Times News Corp ↘ 1.67% reported on Sunday, citing people familiar with the matter. The potential combination, valued at nearly $400 billion, would rank among the largest transactions in pharmaceutical industry history.straitstimes+2

Talks Could Materialize Soon — or Fall Apart

The two companies have held discussions on a potential tie-up in recent months, according to the FT report, though a deal could also be delayed or collapse entirely. AstraZeneca declined to comment, while Bristol Myers Squibb did not immediately respond to a Reuters request for comment outside regular business hours.investing+2

The potential merger comes as AstraZeneca has undergone a dramatic transformation under CEO Pascal Soriot's 14-year leadership, with the company's share price more than quadrupling during his tenure, outpacing the broader FTSE 100 index and British rival GSK ↘ 0.73%. Last year, AstraZeneca unveiled plans for a direct U.S. listing, aiming to capitalize on stronger valuations in the American market while maintaining its London listing.kelo+1

Strategic Rationale

AstraZeneca's second-quarter results last week showed continued strong demand for its cancer and rare disease drugs. Cancer treatments accounted for about $25 billion in 2025 sales — nearly half of the company's total revenue — followed by cardiovascular, renal, and metabolism treatments worth approximately $12 billion.investing+1

A combination with Bristol Myers Squibb would bring together two major oncology-focused portfolios, potentially creating one of the world's largest pharmaceutical groups. The report of the potential deal comes about a dozen years after AstraZeneca fended off a takeover attempt by larger U.S. rival Pfizer ↗ 0.40%.kelo+2